Back To: Home : Featured Technology : Flow Cytometry

CLICK HERE FOR WHAT'S NEW IN:
 

A microbiome meet-up
April 2020
SHARING OPTIONS:

ROCKVILLE, Md. & MARSEILLE, France—A strategic partnership has begun between CosmosID Inc. and Biomeostasis SAS to offer standardized, end-to-end services for preclinical development of next-generation microbiome-based health products. The partners will work to integrate in-vivo pharmacodynamic studies offered by Biomeostasis' rodent facility with CosmosID's standardized GLP workflows and microbiome analysis.
 
Dr. Julien Roux, chief scientific officer of Biomeostasis, noted, "For the past few years, a fast-growing body of evidence has highlighted a causal role, or at least a major involvement, of the microbiome in the development of various pathologies. Concomitantly, many life science companies developing microbiome-oriented/based products have popped up, with an increasing demand of microbiome analysis. We are extremely pleased to partner with microbiome industry leaders, CosmosID, to thereby take microbiome standardization and analysis to the next level for our customers."

Back


PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.